Immunitybio, Inc.
Clinical trials sponsored by Immunitybio, Inc., explained in plain language.
-
New immune therapy aims to save lives in severe pneumonia
Disease control Not yet recruitingThis study tests whether adding an experimental drug (nogapendekin alfa inbakicept) and special immune cells (iNKT cells) to standard care can lower the death rate in critically ill adults with severe pneumonia, often complicated by sepsis or lung failure. About 10 participants i…
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Chemo-Free hope: new cell combo targets tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests a chemotherapy-free combination of two experimental cell therapies (CD19 t-haNK and NAI) plus the drug rituximab in 20 adults with relapsed or refractory B-cell indolent non-Hodgkin lymphoma. The goal is to see if the treatment can shrink tumors and impro…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New immune combo aims to rescue ICU patients from severe pneumonia
Disease control Not yet recruitingThis early study tests whether adding two immune-boosting treatments—nogapendekin alfa inbakicept (injections) and donor immune cells (iNKT cells)—to standard care can help critically ill adults with severe pneumonia recover. About 20 ICU patients will receive the therapy and be …
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC